Form 4: Labcorp CAO reports award vesting and sale

Labcorp SVP/Chief Accounting Officer Peter J. Wilkinson received 2,388 shares from a performance award, withheld 755 for taxes, and sold 1,633 under a Rule 10b5-1 plan, ending with 1,852 shares.

Summary

• On 2026-03-26, Peter J. Wilkinson (SVP, Chief Accounting Officer) acquired 2,388 Labcorp common shares at $0 pursuant to a performance award granted on 2023-02-07 for the three-year period ended 2025-12-31.
• On 2026-03-26, 755 shares were withheld at $268.38 to satisfy tax withholding obligations.
• On 2026-03-27, 1,633 shares were sold at $267.05 under a Rule 10b5-1 trading plan.
• Direct beneficial ownership after the reported transactions is 1,852.2194 shares.
• A Rule 10b5-1(c) plan was indicated for at least one transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine insider transaction involving award vesting, tax withholding, and a pre-planned sale.

Positives

• Receipt of shares from a previously granted three-year performance award (2,388 shares on 2026-03-26).
• Use of a Rule 10b5-1 trading plan for the sale, supporting pre-arranged and compliant execution.
• Clear disclosure of tax withholding via share withholding (755 shares at $268.38).

Negatives

• Net share disposition following vesting and withholding, including an open-market sale of 1,633 shares at $267.05.
• Direct holdings decreased from 4,240.2194 shares (post-vesting) to 1,852.2194 shares after transactions.

Future Outlook

NA

Management Comments

• Shares were acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023 for the three-year period ended December 31, 2025.
• A portion of shares was withheld to satisfy tax withholding obligations.
• The sale on March 27, 2026 was executed under a Rule 10b5-1 trading plan.

Industry Context

StockSavvy.ai notes that executive share vesting, tax withholding via share delivery, and sales under Rule 10b5-1 plans are common across large-cap healthcare and diagnostics companies and typically reflect routine compensation and liquidity management rather than a change in business fundamentals.

Comparison to Industry Standards

• Use of Rule 10b5-1 trading plans aligns with best-practice compliance approaches seen at peers such as Quest Diagnostics (DGX) and Thermo Fisher Scientific (TMO).
• The transaction size (1,633 shares sold) appears immaterial relative to typical insider trades at large-cap healthcare firms and to Labcorp’s market capitalization, consistent with routine post-vesting rebalancing.

Stakeholder Impact

• No operational or governance changes disclosed; minimal direct impact on customers, suppliers, or employees.
• Shareholders may note the insider sale, though it was executed under a Rule 10b5-1 plan.

Key Dates

Keywords

Labcorp, LH, Form 4, insider transaction, Rule 10b5-1, performance award, stock withholding, insider sale, Peter J. Wilkinson, Chief Accounting Officer